Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CPB1 | P15086 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL20293503 | 0.83 | FASN (0.38) | FASNTSHRF10MAOAKDM1A | |
| SCHEMBL20293481 | 0.77 | MME (0.34) | FASN | |
| SCHEMBL20293628 | 0.77 | MME (0.34) | FASN | |
| SCHEMBL1864984 | 0.75 | BTK (0.48) | KMT2AMAOAKDM1AMAOB | |
| SCHEMBL20293666 | 0.73 | POLB (0.38) | KMT2AMEN1TSHRALDH1A1EPHX2 | |
| SCHEMBL4114852 | 0.72 | — | — | |
| SCHEMBL20293588 | 0.71 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL4688598 | 0.71 | F10 (0.64) | F10 | |
| SCHEMBL20328944 | 0.71 | MME (0.31) | — | |
| Water SCHEMBL14908947 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | APOTEX INC. (CA) | 2019-05-28 | — | — | US | disclosed |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301322-B2 | Processes for the preparation of edoxaban and intermediates thereof | VKORC1, CYP2C9, VKORC1L1 | FASN 1917/4885KMT2A 1831/4885MEN1 1974/4885 |
| US-20180179226-A1 | Processes for the Preparation of Edoxaban and Intermediates Thereof | VKORC1, CYP2C9, VKORC1L1 | FASN 1917/4885KMT2A 1831/4885MEN1 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.